Business Description
Aardvark Therapeutics Inc
NAICS : 541715
SIC : 2833
ISIN : US0029421007
Total Employee Number:
40Description
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 271.43 | |||||
Equity-to-Asset | 0.88 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -42.4 | |||||
3-Year EPS without NRI Growth Rate | -38.4 | |||||
3-Year FCF Growth Rate | -36.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 69.88 | |||||
9-Day RSI | 65.36 | |||||
14-Day RSI | 58.49 | |||||
3-1 Month Momentum % | 19.66 | |||||
6-1 Month Momentum % | -69.23 | |||||
12-1 Month Momentum % | -69.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.06 | |||||
Quick Ratio | 8.06 | |||||
Cash Ratio | 7.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.7 | |||||
Shareholder Yield % | 0.12 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -57.88 | |||||
ROA % | -53.46 | |||||
ROIC % | -1246.44 | |||||
3-Year ROIIC % | -630.02 | |||||
ROC (Joel Greenblatt) % | -16881.83 | |||||
ROCE % | -61.82 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.2 | |||||
Price-to-Tangible-Book | 1.2 | |||||
EV-to-EBIT | -0.18 | |||||
EV-to-EBITDA | -0.18 | |||||
EV-to-Forward-Revenue | 24.61 | |||||
EV-to-FCF | -0.22 | |||||
| Price-to-Net-Current-Asset-Value | 1.27 | |||||
| Price-to-Net-Cash | 1.31 | |||||
Earnings Yield (Greenblatt) % | -555.56 | |||||
FCF Yield % | -59 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AARD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aardvark Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.21 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 125.35 | ||
| 14-Day RSI | 58.49 | ||
| 14-Day ATR ($) | 0.451195 | ||
| 20-Day SMA ($) | 4.006 | ||
| 12-1 Month Momentum % | -69.7 | ||
| 52-Week Range ($) | 3.35 - 17.94 | ||
| Shares Outstanding (Mil) | 21.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aardvark Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aardvark Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 138 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 46 days | ||
| General meeting for 2025 | 2026-06-30 | In 2 days | ||
| First quarter earnings results for 2026 | 2026-05-07 | 5.89 (+7.29%) | ||
| Annual report for 2025 | 2026-03-23 | 4.07 (-15.91%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-23 | 4.07 (-15.91%) | ||
| Evercore ISI 8th Annual Healthcare Conference | 2025-12-04 11:15 | 11.93 (+14.38%) | ||
| Piper Sandler 37th Annual Healthcare Conference | 2025-12-03 08:00 | 9.26 (-2.53%) | ||
| TD Cowen Treatment Advancements in Obesity & Related Disorders Summit | 2025-11-24 15:00 | 9.37 (-0.64%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 10.73 (-3.94%) |
Show
Entries
Aardvark Therapeutics Inc Frequently Asked Questions
What is Aardvark Therapeutics Inc(AARD)'s stock price today?
The current price of AARD is $4.79. The 52 week high of AARD is $17.94 and 52 week low is $3.35.
When is next earnings date of Aardvark Therapeutics Inc(AARD)?
The next earnings date of Aardvark Therapeutics Inc(AARD) is 2026-08-13 Est..
Does Aardvark Therapeutics Inc(AARD) pay dividends? If so, how much?
Aardvark Therapeutics Inc(AARD) does not pay dividend.
Guru Commentaries on NAS:AARD
No articles.
Press Release
Articles on Aardvark Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers